{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T01:02:34Z","timestamp":1772931754550,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,12,14]],"date-time":"2015-12-14T00:00:00Z","timestamp":1450051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,12,14]],"date-time":"2015-12-14T00:00:00Z","timestamp":1450051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The generation of a targeting agent that strictly binds to IL13R\u03b12 will significantly expand the therapeutic potential for the treatment of IL13R\u03b12-expressing cancers. In order to fulfill this goal, we generated a single-chain antibody (scFv47) from our parental IL13R\u03b12 monoclonal antibody and tested its binding properties. Furthermore, to demonstrate the potential therapeutic applicability of scFv47, we engineered an adenovirus by incorporating scFv47 as the targeting moiety in the viral fiber and characterized its properties <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo.<\/jats:italic> The scFv47 binds to human recombinant IL13R\u03b12, but not to IL13R\u03b11 with a high affinity of 0.9 \u00b7 10<jats:sup>\u22129<\/jats:sup> M, similar to that of the parental antibody. Moreover, the scFv47 successfully redirects adenovirus to IL13R\u03b12 expressing glioma cells both <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic>. Our data validate scFv47 as a highly selective IL13R\u03b12 targeting agent and justify further development of scFv47-modified oncolytic adenovirus and other therapeutics for the treatment of IL13R\u03b12-expressing glioma and other malignancies.<\/jats:p>","DOI":"10.1038\/srep18133","type":"journal-article","created":{"date-parts":[[2015,12,14]],"date-time":"2015-12-14T11:00:48Z","timestamp":1450090848000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["A novel single-chain antibody redirects adenovirus to IL13R\u03b12-expressing brain tumors"],"prefix":"10.1038","volume":"5","author":[{"given":"Julius W.","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob S.","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Solomaha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak","family":"Kanojia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maciej S.","family":"Lesniak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina V.","family":"Balyasnikova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,12,14]]},"reference":[{"key":"BFsrep18133_CR1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352, 987\u2013996, 10.1056\/NEJMoa043330 (2005).","journal-title":"N Engl J Med"},{"key":"BFsrep18133_CR2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/jgm.1008","volume":"9","author":"S Zheng","year":"2007","unstructured":"Zheng, S. et al. Fiber-knob modifications enhance adenoviral tropism and gene transfer in malignant glioma. The journal of gene medicine 9, 151\u2013160, 10.1002\/jgm.1008 (2007).","journal-title":"The journal of gene medicine"},{"key":"BFsrep18133_CR3","doi-asserted-by":"publisher","first-page":"583","DOI":"10.3171\/jns.2006.104.4.583","volume":"104","author":"WJ Van Houdt","year":"2006","unstructured":"Van Houdt, W. J. et al. The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma. J Neurosurg 104, 583\u2013592, 10.3171\/jns.2006.104.4.583 (2006).","journal-title":"J Neurosurg"},{"key":"BFsrep18133_CR4","doi-asserted-by":"publisher","first-page":"679","DOI":"10.4161\/cbt.6.5.3957","volume":"6","author":"IV Ulasov","year":"2007","unstructured":"Ulasov, I. V. et al. Comparative evaluation of survivin, midkine and CXCR4 promoters for transcriptional targeting of glioma gene therapy. Cancer biology & therapy 6, 679\u2013685 (2007).","journal-title":"Cancer biology & therapy"},{"key":"BFsrep18133_CR5","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1089\/hum.2007.002","volume":"18","author":"IV Ulasov","year":"2007","unstructured":"Ulasov, I. V. et al. Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma. Human gene therapy 18, 589\u2013602, 10.1089\/hum.2007.002 (2007).","journal-title":"Human gene therapy"},{"key":"BFsrep18133_CR6","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1038\/sj.bjc.6604969","volume":"100","author":"IV Ulasov","year":"2009","unstructured":"Ulasov, I. V. et al. Combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptotic cell death in vivo. British journal of cancer 100, 1154\u20131164, 10.1038\/sj.bjc.6604969 (2009).","journal-title":"British journal of cancer"},{"key":"BFsrep18133_CR7","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1200\/JCO.2002.20.4.1063","volume":"20","author":"A Chakravarti","year":"2002","unstructured":"Chakravarti, A. et al. Quantitatively determined survivin expression levels are of prognostic value in human gliomas. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 20, 1063\u20131068 (2002).","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"BFsrep18133_CR8","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s11060-004-2353-3","volume":"72","author":"M Uematsu","year":"2005","unstructured":"Uematsu, M. et al. Prognostic significance of the immunohistochemical index of survivin in glioma: a comparative study with the MIB-1 index. Journal of neuro-oncology 72, 231\u2013238, 10.1007\/s11060-004-2353-3 (2005).","journal-title":"Journal of neuro-oncology"},{"key":"BFsrep18133_CR9","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1073\/pnas.1219817110","volume":"110","author":"BD Choi","year":"2013","unstructured":"Choi, B. D. et al. Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma. Proceedings of the National Academy of Sciences of the United States of America 110, 270\u2013275, 10.1073\/pnas.1219817110 (2013).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"BFsrep18133_CR10","doi-asserted-by":"publisher","first-page":"5949","DOI":"10.1158\/1078-0432.CCR-12-0319","volume":"18","author":"S Kong","year":"2012","unstructured":"Kong, S. et al. Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells. Clinical cancer research: an official journal of the American Association for Cancer Research 18, 5949\u20135960, 10.1158\/1078-0432.CCR-12-0319 (2012).","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"key":"BFsrep18133_CR11","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.jcyt.2014.02.012","volume":"16","author":"S Krebs","year":"2014","unstructured":"Krebs, S. et al. T cells redirected to interleukin-13Ralpha2 with interleukin-13 mutein\u2013chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Ralpha1. Cytotherapy 16, 1121\u20131131, 10.1016\/j.jcyt.2014.02.012 (2014).","journal-title":"Cytotherapy"},{"key":"BFsrep18133_CR12","doi-asserted-by":"crossref","unstructured":"Riccione, K. et al. Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care. Journal of visualized experiments: JoVE, 10.3791\/52397 (2015).","DOI":"10.3791\/52397"},{"key":"BFsrep18133_CR13","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/1471-2407-13-83","volume":"13","author":"IM Zitron","year":"2013","unstructured":"Zitron, I. M. et al. Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies. BMC cancer 13, 83, 10.1186\/1471-2407-13-83 (2013).","journal-title":"BMC cancer"},{"key":"BFsrep18133_CR14","first-page":"1253","volume":"1","author":"W Debinski","year":"1995","unstructured":"Debinski, W., Obiri, N. I., Powers, S. K., Pastan, I. & Puri, R. K. Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin. Clinical cancer research: an official journal of the American Association for Cancer Research 1, 1253\u20131258 (1995).","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"key":"BFsrep18133_CR15","first-page":"1168","volume":"60","author":"BH Joshi","year":"2000","unstructured":"Joshi, B. H., Plautz, G. E. & Puri, R. K. Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas. Cancer Res 60, 1168\u20131172 (2000).","journal-title":"Cancer Res"},{"key":"BFsrep18133_CR16","doi-asserted-by":"publisher","first-page":"7983","DOI":"10.1158\/0008-5472.CAN-07-1493","volume":"67","author":"JS Jarboe","year":"2007","unstructured":"Jarboe, J. S., Johnson, K. R., Choi, Y., Lonser, R. R. & Park, J. K. Expression of interleukin-13 receptor alpha2 in glioblastoma multiforme: implications for targeted therapies. Cancer Res 67, 7983\u20137986, 10.1158\/0008-5472.CAN-07-1493 (2007).","journal-title":"Cancer Res"},{"key":"BFsrep18133_CR17","doi-asserted-by":"publisher","first-page":"e77769","DOI":"10.1371\/journal.pone.0077769","volume":"8","author":"CE Brown","year":"2013","unstructured":"Brown, C. E. et al. Glioma IL13R\u03b12 Is Associated with Mesenchymal Signature Gene Expression and Poor Patient Prognosis. PLoS One 8, e77769, 10.1371\/journal.pone.0077769 (2013).","journal-title":"PLoS One"},{"key":"BFsrep18133_CR18","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1089\/hum.2006.146","volume":"18","author":"IV Ulasov","year":"2007","unstructured":"Ulasov, I. V., Tyler, M. A., Han, Y., Glasgow, J. N. & Lesniak, M. S. Novel recombinant adenoviral vector that targets the interleukin-13 receptor alpha2 chain permits effective gene transfer to malignant glioma. Human gene therapy 18, 118\u2013129, 10.1089\/hum.2006.146 (2007).","journal-title":"Human gene therapy"},{"key":"BFsrep18133_CR19","doi-asserted-by":"publisher","first-page":"30215","DOI":"10.1074\/jbc.M112.370015","volume":"287","author":"IV Balyasnikova","year":"2012","unstructured":"Balyasnikova, I. V. et al. Characterization and immunotherapeutic implications for a novel antibody targeting interleukin (IL)-13 receptor alpha2. The Journal of biological chemistry 287, 30215\u201330227, 10.1074\/jbc.M112.370015 (2012).","journal-title":"The Journal of biological chemistry"},{"key":"BFsrep18133_CR20","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1158\/0008-5472.can-14-3650","volume":"75","author":"RA Bartolom\u00e9","year":"2015","unstructured":"Bartolom\u00e9, R. A. et al. IL13 Receptor \u03b12 Signaling Requires a Scaffold Protein, FAM120A, to Activate the FAK and PI3K Pathways in Colon Cancer Metastasis. Cancer Res 75, 2434\u20132444, 10.1158\/0008-5472.can-14-3650 (2015).","journal-title":"Cancer Res"},{"key":"BFsrep18133_CR21","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/sj.gt.3302603","volume":"13","author":"SJ Hedley","year":"2006","unstructured":"Hedley, S. J. et al. An adenovirus vector with a chimeric fiber incorporating stabilized single chain antibody achieves targeted gene delivery. Gene Ther 13, 88\u201394, 10.1038\/sj.gt.3302603 (2006).","journal-title":"Gene Ther"},{"key":"BFsrep18133_CR22","doi-asserted-by":"publisher","first-page":"4176","DOI":"10.1128\/JVI.75.9.4176-4183.2001","volume":"75","author":"V Krasnykh","year":"2001","unstructured":"Krasnykh, V., Belousova, N., Korokhov, N., Mikheeva, G. & Curiel, D. T. Genetic targeting of an adenovirus vector via replacement of the fiber protein with the phage T4 fibritin. Journal of virology 75, 4176\u20134183, 10.1128\/JVI.75.9.4176-4183.2001 (2001).","journal-title":"Journal of virology"},{"key":"BFsrep18133_CR23","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/labinvest.2014.82","volume":"94","author":"SA Kaliberov","year":"2014","unstructured":"Kaliberov, S. A. et al. Adenoviral targeting using genetically incorporated camelid single variable domains. Laboratory investigation; a journal of technical methods and pathology 94, 893\u2013905, 10.1038\/labinvest.2014.82 (2014).","journal-title":"Laboratory investigation; a journal of technical methods and pathology"},{"key":"BFsrep18133_CR24","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/0022-1759(96)00115-9","volume":"196","author":"SM Kipriyanov","year":"1996","unstructured":"Kipriyanov, S. M., Kupriyanova, O. A., Little, M. & Moldenhauer, G. Rapid detection of recombinant antibody fragments directed against cell-surface antigens by flow cytometry. Journal of immunological methods 196, 51\u201362 (1996).","journal-title":"Journal of immunological methods"},{"key":"BFsrep18133_CR25","first-page":"447","volume":"94","author":"L Toleikis","year":"2004","unstructured":"Toleikis, L., Broders, O. & Dubel, S. Cloning single-chain antibody fragments (scFv) from hybridoma cells. Methods in molecular medicine 94, 447\u2013458 (2004).","journal-title":"Methods in molecular medicine"},{"key":"BFsrep18133_CR26","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/j.1749-6632.1999.tb09409.x","volume":"886","author":"DT Curiel","year":"1999","unstructured":"Curiel, D. T. Strategies to adapt adenoviral vectors for targeted delivery. Annals of the New York Academy of Sciences 886, 158\u2013171 (1999).","journal-title":"Annals of the New York Academy of Sciences"},{"key":"BFsrep18133_CR27","doi-asserted-by":"crossref","unstructured":"Kim, J. W. et al. A Genetically Modified Adenoviral Vector with a Phage Display Derived Peptide Incorporated into Fiber Fibritin Chimera Prolongs Survival in Experimental Glioma. Human gene therapy, 10.1089\/hum.2015.008 (2015).","DOI":"10.1089\/hum.2015.008"},{"key":"BFsrep18133_CR28","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1126\/science.275.5304.1320","volume":"275","author":"JM Bergelson","year":"1997","unstructured":"Bergelson, J. M. et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science (New York, N.Y.) 275, 1320\u20131323 (1997).","journal-title":"Science (New York, N.Y.)"},{"key":"BFsrep18133_CR29","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1073\/pnas.94.7.3352","volume":"94","author":"RP Tomko","year":"1997","unstructured":"Tomko, R. P., Xu, R. & Philipson, L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proceedings of the National Academy of Sciences of the United States of America 94, 3352\u20133356 (1997).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"BFsrep18133_CR30","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/ijc.10891","volume":"103","author":"J Fuxe","year":"2003","unstructured":"Fuxe, J. et al. Expression of the coxsackie and adenovirus receptor in human astrocytic tumors and xenografts. International journal of cancer. Journal international du cancer 103, 723\u2013729, 10.1002\/ijc.10891 (2003).","journal-title":"International journal of cancer. Journal international du cancer"},{"key":"BFsrep18133_CR31","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.3171\/jns.2000.92.6.1002","volume":"92","author":"K Asaoka","year":"2000","unstructured":"Asaoka, K., Tada, M., Sawamura, Y., Ikeda, J. & Abe, H. Dependence of efficient adenoviral gene delivery in malignant glioma cells on the expression levels of the Coxsackievirus and adenovirus receptor. J Neurosurg 92, 1002\u20131008, 10.3171\/jns.2000.92.6.1002 (2000).","journal-title":"J Neurosurg"},{"key":"BFsrep18133_CR32","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1038\/mt.2008.152","volume":"16","author":"C Allen","year":"2008","unstructured":"Allen, C. et al. Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity. Mol Ther 16, 1556\u20131564, 10.1038\/mt.2008.152 (2008).","journal-title":"Mol Ther"},{"key":"BFsrep18133_CR33","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1158\/1535-7163.mct-07-2131","volume":"7","author":"M Kioi","year":"2008","unstructured":"Kioi, M., Seetharam, S. & Puri, R. K. Targeting IL-13Ralpha2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxin. Mol Cancer Ther 7, 1579\u20131587, 10.1158\/1535-7163.mct-07-2131 (2008).","journal-title":"Mol Cancer Ther"},{"key":"BFsrep18133_CR34","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1093\/neuonc\/nop054","volume":"12","author":"S Kunwar","year":"2010","unstructured":"Kunwar, S. et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro-oncology 12, 871\u2013881, 10.1093\/neuonc\/nop054 (2010).","journal-title":"Neuro-oncology"},{"key":"BFsrep18133_CR35","doi-asserted-by":"crossref","unstructured":"Auffinger, B., Spencer, D., Pytel, P., Ahmed, A. U. & Lesniak, M. S. The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence. Expert review of neurotherapeutics, 1\u201312, 10.1586\/14737175.2015.1051968 (2015).","DOI":"10.1586\/14737175.2015.1051968"},{"key":"BFsrep18133_CR36","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1158\/1078-0432.ccr-11-1669","volume":"18","author":"CE Brown","year":"2012","unstructured":"Brown, C. E. et al. Stem-like tumor-initiating cells isolated from IL13Ralpha2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells. Clinical cancer research: an official journal of the American Association for Cancer Research 18, 2199\u20132209, 10.1158\/1078-0432.ccr-11-1669 (2012).","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"key":"BFsrep18133_CR37","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1227\/01.neu.0000316019.28421.95","volume":"62","author":"AT Ogden","year":"2008","unstructured":"Ogden, A. T. et al. Identification of A2B5+CD133- tumor-initiating cells in adult human gliomas. Neurosurgery 62, 505\u2013514; discussion 514-505, 10.1227\/01.neu.0000316019.28421.95 (2008).","journal-title":"Neurosurgery"},{"key":"BFsrep18133_CR38","doi-asserted-by":"publisher","first-page":"7983","DOI":"10.1158\/0008-5472.can-07-1493","volume":"67","author":"JS Jarboe","year":"2007","unstructured":"Jarboe, J. S., Johnson, K. R., Choi, Y., Lonser, R. R. & Park, J. K. Expression of Interleukin-13 Receptor \u03b12 in Glioblastoma Multiforme: Implications for Targeted Therapies. Cancer Research 67, 7983\u20137986, 10.1158\/0008-5472.can-07-1493 (2007).","journal-title":"Cancer Research"},{"key":"BFsrep18133_CR39","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.jocn.2008.12.005","volume":"16","author":"HK Gan","year":"2009","unstructured":"Gan, H. K., Kaye, A. H. & Luwor, R. B. The EGFRvIII variant in glioblastoma multiforme. Journal of clinical neuroscience: official journal of the Neurosurgical Society of Australasia 16, 748\u2013754, 10.1016\/j.jocn.2008.12.005 (2009).","journal-title":"Journal of clinical neuroscience: official journal of the Neurosurgical Society of Australasia"},{"key":"BFsrep18133_CR40","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","volume":"2","author":"GL Beatty","year":"2014","unstructured":"Beatty, G. L. et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer immunology research 2, 112\u2013120, 10.1158\/2326-6066.CIR-13-0170 (2014).","journal-title":"Cancer immunology research"},{"key":"BFsrep18133_CR41","doi-asserted-by":"publisher","first-page":"ii24","DOI":"10.1093\/neuonc\/nou355","volume":"17","author":"JR Kane","year":"2015","unstructured":"Kane, J. R. et al. Sui generis: gene therapy and delivery systems for the treatment of glioblastoma. Neuro-oncology 17 Suppl 2, ii24\u2013ii36, 10.1093\/neuonc\/nou355 (2015).","journal-title":"Neuro-oncology"},{"key":"BFsrep18133_CR42","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.3390\/cancers6041953","volume":"6","author":"MA Patel","year":"2014","unstructured":"Patel, M. A., Kim, J. E., Ruzevick, J., Li, G. & Lim, M. The future of glioblastoma therapy: synergism of standard of care and immunotherapy. Cancers 6, 1953\u20131985, 10.3390\/cancers6041953 (2014).","journal-title":"Cancers"},{"key":"BFsrep18133_CR43","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1101\/gad.235515.113","volume":"28","author":"K Yan","year":"2014","unstructured":"Yan, K. et al. Glioma cancer stem cells secrete Gremlin1 to promote their maintenance within the tumor hierarchy. Genes & development 28, 1085\u20131100, 10.1101\/gad.235515.113 (2014).","journal-title":"Genes & development"},{"key":"BFsrep18133_CR44","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.mvr.2010.09.007","volume":"80","author":"IV Balyasnikova","year":"2010","unstructured":"Balyasnikova, I. V. et al. Cloning and characterization of a single-chain fragment of monoclonal antibody to ACE suitable for lung endothelial targeting. Microvascular research 80, 355\u2013364, 10.1016\/j.mvr.2010.09.007 (2010).","journal-title":"Microvascular research"},{"key":"BFsrep18133_CR45","doi-asserted-by":"publisher","first-page":"e0125851","DOI":"10.1371\/journal.pone.0125851","volume":"10","author":"I Wilkinson-Ryan","year":"2015","unstructured":"Wilkinson-Ryan, I. et al. Incorporation of porcine adenovirus 4 fiber protein enhances infectivity of adenovirus vector on dendritic cells: implications for immune-mediated cancer therapy. PLoS One 10, e0125851, 10.1371\/journal.pone.0125851 (2015).","journal-title":"PLoS One"},{"key":"BFsrep18133_CR46","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402\u2013408, 10.1006\/meth.2001.1262 (2001).","journal-title":"Methods"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep18133.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep18133","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep18133.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T20:26:37Z","timestamp":1672950397000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep18133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,14]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,12,22]]}},"alternative-id":["BFsrep18133"],"URL":"https:\/\/doi.org\/10.1038\/srep18133","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,14]]},"assertion":[{"value":"23 July 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"IB and ML have patent applications in the field of IL13R\u03b12-targeted therapies.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18133"}}